{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:16:32Z","timestamp":1784798192409,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005639","name":"University of Sao Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005639","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Jornal de Pediatria"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jped.2022.11.008","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T15:51:04Z","timestamp":1671637864000},"page":"S62-S69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["Vaccination in children with immune-mediated disorders"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6900-1472","authenticated-orcid":false,"given":"Ana Karolina Barreto Berselli","family":"Marinho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jped.2022.11.008_bib0001","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s10067-018-4367-9","article-title":"The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: a 1-year prospective study","volume":"38","author":"Aygun","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jped.2022.11.008_bib0002","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jped.2022.11.008_bib0003","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/art.37866","article-title":"Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis","volume":"65","author":"Beukelman","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jped.2022.11.008_bib0004","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-018-1780-z","article-title":"Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries","volume":"20","author":"Swart","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jped.2022.11.008_bib0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12969-016-0095-3","article-title":"Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression","volume":"14","author":"Leuvenink","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jped.2022.11.008_bib0006","first-page":"164","article-title":"Vaccination coverage in children with rheumatic diseases","volume":"38","author":"Bizjak","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jped.2022.11.008_bib0007","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1136\/ard.2011.150193","article-title":"EULAR recommendations for vaccination in paediatric patients with rheumatic diseases","volume":"70","author":"Heijstek","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jped.2022.11.008_bib0008","unstructured":"Sociedade Brasileira de Imuniza\u00e7\u00f5es \u2013 SBIm. Calend\u00e1rios de vacina\u00e7\u00e3o SBIm pacientes especiais \u20132021-2022. SBIm 2021. [cited 2022 Nov 1. Available from:https:\/\/sbim.org.br\/noticias\/1445-lancada-edicao-2021-2022-dos-calendarios-de-vacinacao-sbim-pacientes-especiais."},{"key":"10.1016\/j.jped.2022.11.008_bib0009","article-title":"EULAR\/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021","author":"Jansen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jped.2022.11.008_bib0010","unstructured":"Brazil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis. Manual dos Centros de Refer\u00eancia para Imunobiol\u00f3gicos Especiais. 5\u00aa ed. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2019."},{"key":"10.1016\/j.jped.2022.11.008_bib0011","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/341403","article-title":"Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations","volume":"35","author":"Hak","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jped.2022.11.008_bib0012","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1471-2474-13-158","article-title":"Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study","volume":"13","author":"Blumentals","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jped.2022.11.008_bib0013","doi-asserted-by":"crossref","first-page":"O12","DOI":"10.1186\/1546-0096-11-S2-O12","article-title":"PReS-FINAL-2177: safety and lack of autoantibody production following influenza H1N1 vaccination in patients with juvenile idiopathic arthritis (JIA)","volume":"11","author":"Aikawa","year":"2013","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.jped.2022.11.008_bib0014","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3109\/s10165-012-0595-z","article-title":"Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab","volume":"22","author":"Shinoki","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jped.2022.11.008_bib0015","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.vaccine.2011.11.083","article-title":"Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis","volume":"30","author":"Dell'Era","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jped.2022.11.008_bib0016","unstructured":"World Health Organization (WHO). Pneumococcal conjugate vaccines in infants and children under 5 years of age: who position paper \u2013 February 2019."},{"key":"10.1016\/j.jped.2022.11.008_bib0017","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/03009742.2014.984754","article-title":"The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients","volume":"44","author":"Nagel","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jped.2022.11.008_bib0018","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/cid\/civ803","article-title":"Toronto Invasive Bacterial Diseases Network. Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs","volume":"62","author":"Shigayeva","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jped.2022.11.008_bib0019","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/MIB.0000000000000406","article-title":"Immunogenicity of 13-valent pneumococcal conjugate vaccine in pediatric patients with inflammatory bowel disease","volume":"21","author":"Banaszkiewicz","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jped.2022.11.008_bib0020","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1016\/j.vaccine.2010.03.080","article-title":"The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis","volume":"28","author":"Farmaki","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jped.2022.11.008_bib0021","first-page":"204","article-title":"Immunogenicity of 23-valent pneumococcal vaccine in children with systemic lupus erythematosus","volume":"13","author":"Alyasin","year":"2016","journal-title":"Iran J Immunol"},{"key":"10.1016\/j.jped.2022.11.008_bib0022","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.vaccine.2014.12.030","article-title":"Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy","volume":"33","author":"Aikawa","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jped.2022.11.008_bib0023","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1128\/CVI.00682-14","volume":"22","author":"Embree","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jped.2022.11.008_bib0024","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12969-020-0410-x","article-title":"Maintenance of antibody response to diphtheria\/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept","volume":"18","author":"Brunner","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jped.2022.11.008_bib0025","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1136\/annrheumdis-2013-203429","article-title":"Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study","volume":"73","author":"Heijstek","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jped.2022.11.008_bib0026","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1546-0096-11-29","article-title":"Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years","volume":"11","author":"Soybilgic","year":"2013","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jped.2022.11.008_bib0027","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1586\/14760584.2014.943195","article-title":"Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis","volume":"13","author":"Esposito","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jped.2022.11.008_bib0028","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00006454-200206000-00014","article-title":"Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children","volume":"21","author":"Shinefield","year":"2002","journal-title":"Pediatr Infect Dis. J"},{"key":"10.1016\/j.jped.2022.11.008_bib0029","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.vaccine.2020.01.037","article-title":"Live attenuated MMR\/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection","volume":"38","author":"Uziel","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jped.2022.11.008_bib0030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/jinf.2002.0988","article-title":"The effect of vaccination on the epidemiology of varicella zoster virus","volume":"44","author":"Edmunds","year":"2002","journal-title":"J Infect"},{"key":"10.1016\/j.jped.2022.11.008_bib0031","first-page":"791","article-title":"Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus","volume":"30","author":"Barbosa","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jped.2022.11.008_bib0032","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1016\/j.vaccine.2017.04.015","article-title":"Varicella vaccination elicits a humoral and cellular response in children with rheumatic diseases using immune suppressive treatment","volume":"35","author":"Groot","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jped.2022.11.008_bib0033","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s42358-019-0056-x","article-title":"Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases","volume":"59","author":"Pileggi","year":"2019","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.jped.2022.11.008_bib0034","unstructured":"World Health Organization (WHO). COVID-19 disease in children and adolescents: scientific brief, 29 September 2021. [Cited 2022 Nov 15]. Available from:https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Sci_Brief-Children_and_adolescents-2021.1."},{"key":"10.1016\/j.jped.2022.11.008_bib0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00296-020-04749-4","article-title":"Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management","volume":"41","author":"Kabeerdoss","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jped.2022.11.008_bib0036","unstructured":"Office for National Statistics\u2019 website. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. Retrieved on September 17, 2021. [Cited 2022 Nov 15]. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases."},{"key":"10.1016\/j.jped.2022.11.008_bib0037","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s42358-022-00234-7","article-title":"Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force","volume":"62","author":"Tavares","year":"2022","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.jped.2022.11.008_bib0038","unstructured":"Brazil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade Departamento de Imuniza\u00e7\u00e3o e Doen\u00e7as Transmiss\u00edveis Coordena\u00e7\u00e3o-Geral do Programa Nacional de Imuniza\u00e7\u00f5es NOTA T\u00c9CNICA N\u00ba 221\/2022-CGPNI\/DEIDT\/SVS\/MS. [Cited 2022 Nov 15]. Available from: https:\/\/www.gov.br\/saude\/pt-br\/coronavirus\/notas-tecnicas\/2022\/nota-tecnica-221-2022-cgpni-deidt-svs-ms\/view."},{"key":"10.1016\/j.jped.2022.11.008_bib0039","unstructured":"Brazil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade Departamento de Imuniza\u00e7\u00e3o e Doen\u00e7as Transmiss\u00edveis Coordena\u00e7\u00e3o-Geral do Programa Nacional de Imuniza\u00e7\u00f5es NOTA T\u00c9CNICA N\u00ba 114\/2022-CGPNI\/DEIDT\/SVS\/MS. [Cited 2022 Nov 15]. Available from:https:\/\/www.gov.br\/saude\/pt-br\/coronavirus\/notas-tecnicas\/2022\/nota-tecnica-no-114-2022-deidt-svs-ms\/view."},{"key":"10.1016\/j.jped.2022.11.008_bib0040","unstructured":"Brazil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade Departamento de Imuniza\u00e7\u00e3o e Doen\u00e7as Transmiss\u00edveis Coordena\u00e7\u00e3o-Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Nota t\u00e9cnica n\u00ba 213\/2022-CGPNI\/DEIDT\/SVS\/MS. [Cited 2022 Nov 15]. Available from: https:\/\/www.gov.br\/saude\/pt-br\/coronavirus\/notas-tecnicas\/2022\/nota-tecnica-213-2022-cgpni-deidt-svs-ms\/view."},{"key":"10.1016\/j.jped.2022.11.008_bib0041","unstructured":"Brazil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade Departamento de Imuniza\u00e7\u00e3o e Doen\u00e7as Transmiss\u00edveis Coordena\u00e7\u00e3o-Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Nota t\u00e9cnica N\u00ba 02\/2022-CGPNI\/DEIDT\/SVS\/MS. [Cited 2022 Nov 15]. Available from:https:\/\/www.gov.br\/saude\/pt-br\/coronavirus\/notas-tecnicas\/2022\/nota-tecnica-no-2-2022-secovid-gab-secovid-ms\/view."},{"key":"10.1016\/j.jped.2022.11.008_bib0042","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s42358-022-00256-1","article-title":"Update to \u201cguidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force\u201d","volume":"62","author":"Tavares","year":"2022","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.jped.2022.11.008_bib0043","article-title":"EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS- CoV-2: the November 2021 update","volume":"23","author":"Landew\u00e9","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Jornal de Pediatria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021755722001322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021755722001322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T23:24:20Z","timestamp":1758151460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021755722001322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":43,"alternative-id":["S0021755722001322"],"URL":"https:\/\/doi.org\/10.1016\/j.jped.2022.11.008","relation":{},"ISSN":["0021-7557"],"issn-type":[{"value":"0021-7557","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination in children with immune-mediated disorders","name":"articletitle","label":"Article Title"},{"value":"Jornal de Pediatria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jped.2022.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}